ADVERTISEMENT
ADVERTISEMENT

Keeping up the weight loss

Just in time for the New Year's resolution. A randomised, double blind trial suggests that the drug, sibutramine, previously known for inducing dose-dependent weight loss and enhancing the effects of a low-calorie diets, is effective in sustaining weight loss (Lancet 2000; 356: 2119-25). The international team of researchers, lead by Professor W Philip T James from Aberdeen, UK, studied 605 obese patients recruited from eight European centres. The patients were enrolled in a 6-month period of we

Tudor Toma(ttoma@mail.dntis.ro)

Just in time for the New Year's resolution. A randomised, double blind trial suggests that the drug, sibutramine, previously known for inducing dose-dependent weight loss and enhancing the effects of a low-calorie diets, is effective in sustaining weight loss (Lancet 2000; 356: 2119-25).

The international team of researchers, lead by Professor W Philip T James from Aberdeen, UK, studied 605 obese patients recruited from eight European centres. The patients were enrolled in a 6-month period of weight loss treatment with sibutramine (10 mg/day) and an individualised dietary programme; 467 (77%) achieved more than 5% weight loss and were eligible for the second phase of the trial where they were randomly assigned either 10 mg/day of sibutramine (352 patients) or placebo (115 patients) for a further 18 months. Of the 204 sibutramine-treated patients who completed the trial, 89 (43%) maintained 80% or more of their original weight loss, compared with...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
ADVERTISEMENT